aTYR PHARMA (ATYR) EBIAT (2019 - 2025)
aTYR PHARMA's EBIAT history spans 7 years, with the latest figure at -$14.0 million for Q4 2025.
- For Q4 2025, EBIAT rose 6.71% year-over-year to -$14.0 million; the TTM value through Dec 2025 reached -$74.1 million, down 15.77%, while the annual FY2025 figure was -$74.1 million, 15.77% down from the prior year.
- EBIAT reached -$14.0 million in Q4 2025 per ATYR's latest filing, up from -$25.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$7.2 million in Q1 2021 to a low of -$25.7 million in Q3 2025.
- Average EBIAT over 5 years is -$13.4 million, with a median of -$12.8 million recorded in 2022.
- Peak YoY movement for EBIAT: plummeted 508.39% in 2021, then rose 14.38% in 2023.
- A 5-year view of EBIAT shows it stood at -$8.6 million in 2021, then grew by 12.12% to -$7.5 million in 2022, then tumbled by 96.11% to -$14.8 million in 2023, then dropped by 1.45% to -$15.0 million in 2024, then increased by 6.71% to -$14.0 million in 2025.
- Per Business Quant, the three most recent readings for ATYR's EBIAT are -$14.0 million (Q4 2025), -$25.7 million (Q3 2025), and -$19.5 million (Q2 2025).